Takeshi Iwatsubo

Takeshi Iwatsubo's AcademicInfluence.com Rankings

Takeshi Iwatsubo

Philosophy

#4454

World Rank

#6970

Historical Rank

Logic

#1902

World Rank

#2770

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Takeshi Iwatsubo's Degrees

Doctorate Medicine University of Tokyo
PhD Medicine University of Tokyo

Why Is Takeshi Iwatsubo Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Takeshi Iwatsubo's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) (5616)
Diagnosis and management of dementia with Lewy bodies (2005) (3346)
α-Synuclein is phosphorylated in synucleinopathy lesions (2002) (1579)
Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43) (1994) (1560)
APP Processing and Synaptic Function (2003) (1543)
Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) (1494)
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. (1998) (1493)
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. (2014) (1327)
AMPAR Removal Underlies Aβ-Induced Synaptic Depression and Dendritic Spine Loss (2006) (1018)
A phase 3 trial of semagacestat for treatment of Alzheimer's disease. (2013) (906)
Unravelling angiosperm genome evolution by phylogenetic analysis of chromosomal duplication events (883)
alpha-Synuclein is phosphorylated in synucleinopathy lesions. (2002) (847)
The role of presenilin cofactors in the γ-secretase complex (2003) (779)
Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α‐synuclein (1998) (625)
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup (2011) (624)
Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). (1994) (567)
Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' (1998) (548)
Dominant and differential deposition of distinct β-amyloid peptide species, Aβ N3(pE), in senile plaques (1995) (515)
Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. (1998) (497)
Inhibition of Heparin-induced Tau Filament Formation by Phenothiazines, Polyphenols, and Porphyrins* (2005) (485)
Alzheimer's Aβ(1–42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells (1997) (451)
Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein* (2000) (437)
Mechanism of Ca2+ Disruption in Alzheimer's Disease by Presenilin Regulation of InsP3 Receptor Channel Gating (2008) (434)
[Alzheimer's disease Neuroimaging Initiative (ADNI)]. (2011) (413)
Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease. (2012) (399)
Effects of PS1 Deficiency on Membrane Protein Trafficking in Neurons (1998) (373)
Aggresomes Formed by α-Synuclein and Synphilin-1 Are Cytoprotective* (2004) (360)
DLB and PDD boundary issues (2007) (351)
The role of presenilin cofactors in the gamma-secretase complex. (2003) (350)
Phosphorylated α-Synuclein Is Ubiquitinated in α-Synucleinopathy Lesions* (2002) (347)
The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. (1997) (343)
Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan (1998) (339)
Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in down Syndrome (1995) (336)
Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. (2004) (318)
A Loss of Function Mutation of Presenilin-2 Interferes with Amyloid β-Peptide Production and Notch Signaling* (1999) (318)
Accumulation of Phosphorylated α‐Synuclein in Aging Human Brain (2003) (316)
Cell–matrix interaction via CD44 is independently regulated by different metalloproteinases activated in response to extracellular Ca2+ influx and PKC activation (2004) (305)
Small Molecule Inhibitors of α-Synuclein Filament Assembly† (2006) (303)
Neprilysin Degrades Both Amyloid β Peptides 1–40 and 1–42 Most Rapidly and Efficiently among Thiorphan- and Phosphoramidon-sensitive Endopeptidases* (2001) (299)
Endoplasmic Reticulum Stress Is Important for the Manifestations of α-Synucleinopathy In Vivo (2012) (298)
Misfolded proteinase K–resistant hyperphosphorylated α-synuclein in aged transgenic mice with locomotor deterioration and in human α-synucleinopathies (2002) (283)
GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. (2007) (281)
Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia (1998) (274)
Hyperphosphorylation and insolubility of α‐synuclein in transgenic mouse oligodendrocytes (2002) (271)
Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain (1996) (270)
Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. (1996) (250)
LRRK2 Modulates Vulnerability to Mitochondrial Dysfunction in Caenorhabditis elegans (2009) (245)
Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. (2004) (243)
Overexpression of α‐synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of α‐synuclein and activation of caspase‐9: resemblance to pathogenetic changes in Parkinson's disease (2004) (236)
Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases. (2010) (233)
Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. (2000) (232)
Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. (2000) (229)
Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity (2008) (222)
G Protein-Mediated Neuronal DNA Fragmentation Induced by Familial Alzheimer's Disease-Associated Mutants of APP (1996) (219)
Selective Insolubility of α-Synuclein in Human Lewy Body Diseases Is Recapitulated in a Transgenic Mouse Model (2001) (219)
High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy. (1994) (216)
Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. (2002) (216)
Biochemical Characterization of the Core Structure of α-Synuclein Filaments* (2002) (214)
CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC‐P/collagen type XXV (2002) (212)
Presenilins mediate a dual intramembranous γ‐secretase cleavage of Notch‐1 (2002) (210)
Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. (2008) (208)
Gain-of-Function Enhancement of IP3 Receptor Modal Gating by Familial Alzheimer’s Disease–Linked Presenilin Mutants in Human Cells and Mouse Neurons (2010) (204)
Neurological and Neurodegenerative Alterations in a Transgenic Mouse Model Expressing Human α-Synuclein under Oligodendrocyte Promoter: Implications for Multiple System Atrophy (2005) (202)
Amyloid Phenotype Characterization of Transgenic Mice Overexpressing both Mutant Amyloid Precursor Protein and Mutant Presenilin 1 Transgenes (1999) (200)
A presenilin dimer at the core of the γ-secretase enzyme: Insights from parallel analysis of Notch 1 and APP proteolysis (2003) (198)
Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. (1995) (195)
Amyloid β protein (Aβ) deposition in chromosome 14–linked Alzheimer's disease: Predominance of Aβ42(43) (1996) (194)
Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. (2002) (191)
C-terminal Fragment of Presenilin Is the Molecular Target of a Dipeptidic γ-Secretase-specific Inhibitor DAPT (N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-Butyl Ester)* (2006) (189)
Accumulation of phosphorylated alpha-synuclein in aging human brain. (2003) (188)
Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. (1996) (187)
The Amyloid-β Pathway in Alzheimer’s Disease (2021) (185)
Lewy Body Pathology Involves Cutaneous Nerves (2008) (185)
Familial Parkinson Mutant α-Synuclein Causes Dopamine Neuron Dysfunction in Transgenic Caenorhabditis elegans* (2006) (184)
World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia (2019) (183)
Amyloid Precursor Proteins Inhibit Heme Oxygenase Activity and Augment Neurotoxicity in Alzheimer's Disease (2000) (182)
Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease (2009) (180)
Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. (2008) (179)
Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease. (2001) (176)
Activity-Dependent Proteolytic Cleavage of Neuroligin-1 (2012) (171)
Sulindac Sulfide Is a Noncompetitive γ-Secretase Inhibitor That Preferentially Reduces Aβ42 Generation* (2003) (170)
BACE1 activity is modulated by cell-associated sphingosine-1-phosphate (2011) (170)
Chronic optogenetic activation augments aβ pathology in a mouse model of Alzheimer disease. (2015) (169)
LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis (2018) (168)
Defective liver formation and liver cell apoptosis in mice lacking the stress signaling kinase SEK1/MKK4. (1999) (163)
Platelet-activating factor (PAF) receptor in rat brain: PAF mobilizes intracellular Ca2+ in hippocampal neurons (1992) (162)
Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. (2002) (162)
Molecular Cloning and Characterization of CALP/KChIP4, a Novel EF-hand Protein Interacting with Presenilin 2 and Voltage-gated Potassium Channel Subunit Kv4* (2002) (159)
Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. (1996) (159)
Selective loss of nigral dopamine neurons induced by overexpression of truncated human α-synuclein in mice (2008) (157)
Evaluation of α-synuclein immunohistochemical methods used by invited experts (2008) (155)
The γ-secretase complex: machinery for intramembrane proteolysis (2004) (154)
Lecanemab in Early Alzheimer's Disease. (2022) (154)
A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in alpha-synuclein transgenic C. elegans. (2008) (151)
Late‐onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation (2002) (148)
Structure of the Catalytic Pore of γ-Secretase Probed by the Accessibility of Substituted Cysteines (2006) (148)
Pick's disease is associated with mutations in the tau gene (2000) (146)
Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. (1998) (144)
The C-Terminal PAL Motif and Transmembrane Domain 9 of Presenilin 1 Are Involved in the Formation of the Catalytic Pore of the γ-Secretase (2008) (142)
Calpain‐mediated degradation of p35 to p25 in postmortem human and rat brains (2001) (142)
Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau (2015) (141)
Presenilin-dependent γ-secretase activity mediates the intramembranous cleavage of CD44 (2003) (136)
Association of active γ-secretase complex with lipid rafts Published, JLR Papers in Press, Feburary 16, 2005. DOI 10.1194/jlr.M400333-JLR200 (2005) (128)
Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. (2008) (121)
A Noncompetitive BACE1 Inhibitor TAK-070 Ameliorates Aβ Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease (2010) (120)
The Role of G-Protein-Coupled Receptor Kinase 5 in Pathogenesis of Sporadic Parkinson's Disease (2006) (120)
Cytoplasmic localization and proteasomal degradation of N-terminally cleaved form of PINK1 (2008) (118)
Presenilins mediate a dual intramembranous gamma-secretase cleavage of Notch-1. (2002) (118)
Familial amyotrophic lateral sclerosis and parkinsonism‐dementia complex of the Kii peninsula of Japan: Clinical and neuropathological study and tau analysis (2001) (117)
Analysis of the Adrenal Gland Is Useful for Evaluating Pathology of the Peripheral Autonomic Nervous System in Lewy Body Disease (2007) (116)
A novel mutation at position +12 in the intron following Exon 10 of the tau gene in familial frontotemporal dementia (FTD‐Kumamoto) (2000) (116)
Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer’s disease (2004) (115)
Phosphorylation of α-synuclein characteristic of synucleinopathy lesions is recapitulated in α-synuclein transgenic Drosophila (2003) (115)
Identification of the autophosphorylation sites of LRRK2. (2009) (111)
[alpha-synuclein and Parkinson's disease]. (2002) (111)
Phenylpiperidine‐type γ‐secretase modulators target the transmembrane domain 1 of presenilin 1 (2011) (108)
Enhancement of amyloid β 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease (1999) (108)
Ubiquitination of α-Synuclein† (2005) (108)
Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. (2001) (107)
The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta 42(43) (1997) (107)
Pen-2 Is Incorporated into the γ-Secretase Complex through Binding to Transmembrane Domain 4 of Presenilin 1* (2005) (107)
Somatodendritic localization of phosphorylated tau in neonatal and adult rat cerebral cortex (1997) (106)
C Terminus of Presenilin Is Required for Overproduction of Amyloidogenic Aβ42 through Stabilization and Endoproteolysis of Presenilin (1999) (106)
Aβ Immunotherapy: Intracerebral Sequestration of Aβ by an Anti-Aβ Monoclonal Antibody 266 with High Affinity to Soluble Aβ (2009) (104)
SEK1/MKK4-mediated SAPK/JNK signaling participates in embryonic hepatoblast proliferation via a pathway different from NF-kappaB-induced anti-apoptosis. (2002) (104)
Aph-1 Contributes to the Stabilization and Trafficking of the γ-Secretase Complex through Mechanisms Involving Intermolecular and Intramolecular Interactions* (2005) (104)
Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of A beta 42(43) and association of A beta 40 with cored plaques. (1996) (103)
The Tottori (D7N) and English (H6R) Familial Alzheimer Disease Mutations Accelerate Aβ Fibril Formation without Increasing Protofibril Formation* (2007) (102)
The Low Density Lipoprotein Receptor-related Protein 1 Mediates Uptake of Amyloid β Peptides in an in Vitro Model of the Blood-Brain Barrier Cells* (2008) (101)
Mutant Presenilin 2 Transgenic Mouse: Effect on an Age‐Dependent Increase of Amyloid β‐Protein 42 in the Brain (1998) (101)
Accumulation of phosphorylated α-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy (2004) (101)
Biochemical characterization of the core structure of alpha-synuclein filaments. (2002) (101)
LRRK2 and RAB7L1 coordinately regulate axonal morphology and lysosome integrity in diverse cellular contexts (2016) (101)
P4-261 Small molecule inhibitors of alpha-synuclein filament assembly (2006) (99)
Epitope mapping of LB509, a monoclonal antibody directed against human α-synuclein (1999) (99)
An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies (2006) (99)
α‐Synuclein Inclusions in Amygdala in the Brains of Patients with the Parkinsonism‐Dementia Complex of Guam (2000) (96)
Major Involvement of Low-Density Lipoprotein Receptor-Related Protein 1 in the Clearance of Plasma Free Amyloid β-Peptide by the Liver (2006) (95)
Localization of D-aspartic acid in elongate spermatids in rat testis. (1998) (95)
Localization of α-tocopherol transfer protein in rat brain (1998) (94)
Variant Alzheimer Disease With Spastic Paraparesis: Neuropathological Phenotype (2001) (93)
Three-dimensional structure of the gamma-secretase complex. (2006) (93)
Preferential deposition of amyloid β protein (Aβ) in the form Aβ 40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele (1997) (92)
Presenilin-dependent intramembrane cleavage of ephrin-B1 (2006) (92)
The First Proline of PALP Motif at the C Terminus of Presenilins Is Obligatory for Stabilization, Complex Formation, and γ-Secretase Activities of Presenilins* (2001) (90)
Attenuation of the aggregation and neurotoxicity of amyloid-β peptides by catalytic photooxygenation. (2014) (90)
D-aspartate uptake into cultured rat pinealocytes and the concomitant effect on L-aspartate levels and melatonin secretion. (1998) (89)
Diffeomorphic Anatomical Registration Through Exponentiated Lie Algebra provides reduced effect of scanner for cortex volumetry with atlas-based method in healthy subjects (2013) (88)
Relationship of phosphorylated α-synuclein and tau accumulation to Aβ deposition in the cerebral cortex of dementia with Lewy bodies (2008) (87)
Quantification of Modified Amyloid β Peptides in Alzheimer Disease and Down Syndrome Brains (1998) (85)
Divergent synthesis of multifunctional molecular probes to elucidate the enzyme specificity of dipeptidic gamma-secretase inhibitors. (2007) (84)
Caveolin-3 Upregulation Activates β-Secretase–Mediated Cleavage of the Amyloid Precursor Protein in Alzheimer’s Disease (1999) (83)
Dyrk1A Phosphorylates α-Synuclein and Enhances Intracellular Inclusion Formation* (2006) (82)
Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human α‐synuclein: Implication for α‐synucleinopathies (2007) (82)
Accumulation of phosphorylated α‐synuclein in dopaminergic neurons of transgenic mice that express human α‐synuclein (2007) (81)
Japanese Alzheimer's Disease Neuroimaging Initiative: Present status and future (2010) (81)
The intracellular domain of the amyloid precursor protein (AICD) enhances the p53-mediated apoptosis. (2006) (81)
Molecular Cloning and Characterization of a Novel Chloride Intracellular Channel-related Protein, Parchorin, Expressed in Water-secreting Cells* (2000) (81)
The gamma-secretase complex: machinery for intramembrane proteolysis. (2004) (80)
Presenilin-dependent gamma-secretase activity mediates the intramembranous cleavage of CD44. (2003) (80)
Pathobiology of the Lewy body. (1999) (78)
The neuropathology of frontotemporal lobar degeneration with respect to the cytological and biochemical characteristics of tau protein (2004) (78)
Phosphorylation of α-Synuclein Protein at Ser-129 Reduces Neuronal Dysfunction by Lowering Its Membrane Binding Property in Caenorhabditis elegans* (2012) (77)
FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-β Production in Neurons (2013) (77)
Biosynthesis of d‐aspartate in mammalian cells 1 (1998) (77)
BIN1 regulates BACE1 intracellular trafficking and amyloid-β production. (2016) (76)
Both Notch1 and Notch2 contribute to the regulation of melanocyte homeostasis (2007) (76)
Decreased CALM expression reduces Aβ42 to total Aβ ratio through clathrin-mediated endocytosis of γ-secretase (2014) (75)
Immunohistochemical localization of D-aspartate in the rat pineal gland. (1997) (75)
Evidence That Intramolecular Associations between Presenilin Domains Are Obligatory for Endoproteolytic Processing* (1999) (75)
Extracellular α-synuclein levels are regulated by neuronal activity (2018) (75)
Co-localization of α-synuclein and phosphorylated tau in neuronal and glial cytoplasmic inclusions in a patient with multiple system atrophy of long duration (2001) (75)
Selective Reconstitution and Recovery of Functional γ-Secretase Complex on Budded Baculovirus Particles*[boxs] (2004) (74)
A Role for Presenilin 1 in Regulating the Delivery of Amyloid Precursor Protein to the Cell Surface (2002) (74)
Emergence of d-aspartic acid in the differentiating neurons of the rat central nervous system (1998) (74)
Parkinson's disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology. (2018) (73)
Molecular dissection of domains in mutant presenilin 2 that mediate overproduction of amyloidogenic forms of amyloid beta peptides. Inability of truncated forms of PS2 with familial Alzheimer's disease mutation to increase secretion of Abeta42. (1998) (72)
Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials (2018) (71)
The Nonconserved Hydrophilic Loop Domain of Presenilin (PS) Is Not Required for PS Endoproteolysis or Enhanced Aβ42 Production Mediated by Familial Early Onset Alzheimer's Disease-linked PS Variants* (2000) (70)
Frontal pure agraphia for kanji or kana: Dissociation between morphology and phonology (1997) (70)
Neutralization of the γ-secretase activity by monoclonal antibody against extracellular domain of nicastrin (2012) (70)
Complex N‐glycosylated form of nicastrin is stabilized and selectively bound to presenilin fragments (2002) (69)
Association of A beta 40-positive senile plaques with microglial cells in the brains of patients with Alzheimer's disease and in non-demented aged individuals. (1996) (68)
Degenerative terminals of the perforant pathway are human α-synuclein-immunoreactive in the hippocampus of patients with diffuse Lewy body disease (1998) (68)
[Amyloid beta peptide]. (2004) (67)
RNA binding mediates neurotoxicity in the transgenic Drosophila model of TDP-43 proteinopathy. (2013) (67)
Juvenile-onset generalized neuroaxonal dystrophy (Hallervorden-Spatz disease) with diffuse neurofibrillary and Lewy body pathology (2000) (67)
Inhibition of gamma-secretase activity by helical beta-peptide foldamers. (2009) (66)
Roles of distinct cysteine residues in S-nitrosylation and dimerization of DJ-1. (2006) (66)
Differential effects of diet- and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimer’s disease (2019) (65)
Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. (2004) (65)
S-Palmitoylation of γ-Secretase Subunits Nicastrin and APH-1* (2009) (65)
Neuronal and glial tau-positive inclusions in diverse neurologic diseases share common phosphorylation characteristics (2004) (64)
Allosteric regulation of γ-secretase activity by a phenylimidazole-type γ-secretase modulator (2014) (64)
α‐Synuclein Accumulates in Purkinje Cells in Lewy Body Disease but not in Multiple System Atrophy (2003) (64)
Association of active gamma-secretase complex with lipid rafts. (2005) (64)
Familial Alzheimer's disease-linked mutations at Val717 of amyloid precursor protein are specific for the increased secretion of A beta 42(43). (1996) (63)
Lack of the car☐yl terminal sequence of tau in ghost tangles of Alzheimer's disease (1993) (63)
Comprehensive phosphoproteome analysis unravels the core signaling network that initiates the earliest synapse pathology in preclinical Alzheimer's disease brain. (2015) (63)
The −48 C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimer's disease and an increased Aβ load in brain (2001) (62)
Neuron-specific methylome analysis reveals epigenetic regulation and tau-related dysfunction of BRCA1 in Alzheimer’s disease (2017) (62)
Structural Interactions between Inhibitor and Substrate Docking Sites Give Insight into Mechanisms of Human PS1 Complexes (2014) (61)
Aβ42 Overproduction Associated with Structural Changes in the Catalytic Pore of γ-Secretase (2007) (61)
LRRK2 in Parkinson's disease and dementia with Lewy bodies (2006) (60)
Amyloid (Aβ) deposition in chromosome 1–linked Alzheimer's disease: The volga german families (1997) (59)
Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. (2003) (59)
Functional analysis of the transmembrane domains of presenilin 1: participation of transmembrane domains 2 and 6 in the formation of initial substrate-binding site of gamma-secretase. (2010) (59)
Apolipoprotein E gene in diffuse Lewy body disease with or without co-existing Alzheimer's disease (1994) (59)
Participation of Transmembrane Domain 1 of Presenilin 1 in the Catalytic Pore Structure of the γ-Secretase (2010) (58)
Relationships in Alzheimer's disease between the extent of Aβ deposition in cerebral blood vessel walls, as cerebral amyloid angiopathy, and the amount of cerebrovascular smooth muscle cells and collagen (2006) (58)
1 SEEDED AGGREGATION AND TOXICITY OF α-SYNUCLEIN AND TAU : CELLULAR MODELS OF NEURODEGENERATIVE DISEASES (2010) (58)
Common anti-apoptotic roles of parkin and α-synuclein in human dopaminergic cells (2005) (57)
d-Aspartate localization in the rat pituitary gland and retina (1999) (57)
Biochemical Characterization of the Drosophila Wingless Signaling Pathway Based on RNA Interference (2004) (56)
Ubiquitination of alpha-synuclein. (2005) (56)
Targeted introduction of V642I mutation in amyloid precursor protein gene causes functional abnormality resembling early stage of Alzheimer's disease in aged mice (2004) (55)
Are interleukin-1 gene polymorphisms risk factors or disease modifiers in AD? (2002) (54)
Monoclonal antibodies to purified cortical lewy bodies recognize the mid‐size neurofilament subunit (1997) (54)
Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. (2003) (54)
Primary cultures of neuronal and non-neuronal rat brain cells secrete similar proportions of amyloid β peptides ending at Aβ40 and Aβ42 (1999) (54)
Aggregation of α-synuclein in the pathogenesis of Parkinson’s disease (2003) (53)
CLAC Binds to Amyloid β Peptides through the Positively Charged Amino Acid Cluster within the Collagenous Domain 1 and Inhibits Formation of Amyloid Fibrils* (2005) (53)
D-aspartic acid localization during postnatal development of rat adrenal gland. (1997) (53)
Subcellular Compartment and Molecular Subdomain of β-Amyloid Precursor Protein Relevant to the Aβ42-promoting Effects of Alzheimer Mutant Presenilin 2* (2001) (53)
Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation. (2006) (53)
Pathological relationships between microglial cell activity and tau and amyloid β protein in patients with Alzheimer's disease (2002) (53)
The angiotensin 1-converting enzyme insertion (I)/deletion (D) polymorphism does not influence the extent of amyloid or tau pathology in patients with sporadic Alzheimer's disease (2002) (51)
Naphthyl and coumarinyl biarylpiperazine derivatives as highly potent human beta-secretase inhibitors. Design, synthesis, and enzymatic BACE-1 and cell assays. (2006) (51)
Enhancement of amyloid beta 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease. (1999) (50)
Diffuse Plaques in the Cerebellum and Corpus Striatum in Down's Syndrome Contain Amyloid β Protein (Aβ) only in the Form of Aβ42(43) (1996) (50)
Is there a relation between APOE expression and brain amyloid load in Alzheimer’s disease? (2005) (50)
Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. (2007) (50)
Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene (2000) (50)
Association of 3′-UTR polymorphisms of the oxidised LDL receptor 1 (OLR1) gene with Alzheimer’s disease (2003) (48)
Molecular cloning and expression of the novel splice variants of K(+) channel-interacting protein 2. (2001) (47)
Amyloid‐β peptide(1‐40) elimination from cerebrospinal fluid involves low‐density lipoprotein receptor‐related protein 1 at the blood‐cerebrospinal fluid barrier (2011) (47)
The Mechanism of γ-Secretase Activities through High Molecular Weight Complex Formation of Presenilins Is Conserved inDrosophila melanogaster and Mammals* (2002) (46)
The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update (2015) (46)
Presenilin 2 regulates the systolic function of heart by modulating Ca2+ signaling (2005) (46)
Cooperative Roles of Hydrophilic Loop 1 and the C-Terminus of Presenilin 1 in the Substrate-Gating Mechanism of γ-Secretase (2015) (46)
Localization, transport, and uptake of D-aspartate in the rat adrenal and pituitary glands. (2001) (45)
Structural Biology of Presenilins and Signal Peptide Peptidases* (2013) (45)
Amyloid β protein deposition in patients with frontotemporal lobar degeneration: relationship to age and apolipoprotein E genotype (2001) (45)
Re-examination of the dimerization state of leucine-rich repeat kinase 2: predominance of the monomeric form. (2012) (45)
ATP-binding cassette transporter A1 (ABCA1) deficiency does not attenuate the brain-to-blood efflux transport of human amyloid-β peptide (1–40) at the blood–brain barrier (2008) (44)
Investigation of Lewy pathology in the visual pathway of brains of dementia with Lewy bodies (2006) (44)
Effect of the APOE promoter polymorphisms on cerebral amyloid peptide deposition in Alzheimer's disease (2001) (43)
Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein. (1999) (43)
Cases of Alzheimer's disease due to deletion of exon 9 of the presenilin‐1 gene show an unusual but characteristic β‐amyloid pathology known as ‘cotton wool’ plaques (2001) (42)
Genetic associations between cathepsin D exon 2 C→T polymorphism and Alzheimer’s disease, and pathological correlations with genotype (2006) (41)
Patterns and severity of vascular amyloid in Alzheimer’s disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer’s disease (2018) (41)
The presenilin 2 loop domain interacts with the mu-calpain C-terminal region. (1998) (41)
Lack of ubiquitin immunoreactivities at both ends of neuropil threads. Possible bidirectional growth of neuropil threads. (1992) (40)
Ultra-high field NMR studies of antibody binding and site-specific phosphorylation of alpha-synuclein. (2007) (40)
Visual-Statistical Interpretation of 18F-FDG-PET Images for Characteristic Alzheimer Patterns in a Multicenter Study: Inter-Rater Concordance and Relationship to Automated Quantitative Evaluation (2014) (40)
Molecular cloning of a novel basic helix-loop-helix protein from the rat brain. (1996) (40)
Ultrastructure of nuclear aggregates formed by expressing an expanded polyglutamine. (2002) (40)
Common anti-apoptotic roles of parkin and alpha-synuclein in human dopaminergic cells. (2005) (40)
Proteomics of Caenorhabditis elegans over-expressing human alpha-synuclein analyzed by fluorogenic derivatization-liquid chromatography/tandem mass spectrometry: identification of actin and several ribosomal proteins as negative markers at early Parkinson's disease stages. (2008) (40)
Amyloid β Protein in Plasma as a Diagnostic Marker for Alzheimer’s Disease (1998) (39)
CLAC-P/Collagen Type XXV Is Required for the Intramuscular Innervation of Motoneurons during Neuromuscular Development (2014) (39)
Phosphorylated α‐synuclein in normal mouse brain (2004) (39)
Tau load is associated with apolipoprotein E genotype and the amount of amyloid β protein, Aβ40, in sporadic and familial Alzheimer's disease (2003) (38)
Alterations in human tau transcripts correlate with those of neurofilament in sporadic tauopathies (2004) (38)
Comparison of extent of tau pathology in patients with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP‐17), frontotemporal lobar degeneration with Pick bodies and early onset Alzheimer’s disease (2006) (38)
Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human alpha-synuclein: Implication for alpha-synucleinopathies. (2007) (37)
Alpha-synuclein accumulates in Purkinje cells in Lewy body disease but not in multiple system atrophy. (2003) (37)
Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting database (2021) (37)
Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease (2004) (37)
Comparison between brain CT and MRI for voxel-based morphometry of Alzheimer's disease (2013) (37)
Analytical Method for β-Amyloid Fibrils Using CE-Laser Induced Fluorescence and Its Application to Screening for Inhibitors of β-Amyloid Protein Aggregation (2007) (36)
Amyloid plaques in Guam amyotrophic lateral sclerosis/ parkinsonism-dementia complex contain species of Aβ similar to those found in the amyloid plaques of Alzheimer’s disease and pathological aging (1998) (36)
Localization of alpha-tocopherol transfer protein in rat brain. (1998) (35)
Glymphatic system clears extracellular tau and protects from tau aggregation and neurodegeneration (2022) (35)
Association study of three polymorphisms of TGF-β1 gene with Alzheimer's disease (2002) (35)
Cerebrospinal fluid levels of amyloid β-peptide1–42, but not tau have positive correlation with brain glucose metabolism in humans (1999) (35)
A FE65 polymorphism associated with risk of developing sporadic late-onset Alzheimer's disease but not with Aβ loading in brains (2000) (35)
Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. (1997) (34)
Abeta42 overproduction associated with structural changes in the catalytic pore of gamma-secretase: common effects of Pen-2 N-terminal elongation and fenofibrate. (2007) (34)
Leucine-Rich Repeat Kinase 2 Colocalizes with α-Synuclein in Parkinson’s Disease, but Not Tau-Containing Deposits in Tauopathies (2008) (34)
The Emerging Functions of LRRK2 and Rab GTPases in the Endolysosomal System (2020) (33)
Role of Apolipoprotein E in β-Amyloidogenesis (2015) (33)
Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43). (1996) (33)
Seeded Aggregation and Toxicity of α-Synuclein and Tau (2010) (33)
Correlation in Lewy pathology between the claustrum and visual areas in brains of dementia with Lewy bodies (2007) (32)
Highly efficient synthesis of medium-sized lactams via intramolecular Staudinger–aza-Wittig reaction of ω-azido pentafluorophenyl ester: synthesis and biological evaluation of LY411575 analogues (2004) (32)
Comparison of Presenilin 1 and Presenilin 2 γ-Secretase Activities Using a Yeast Reconstitution System* (2011) (31)
Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease. (2003) (31)
Association study and meta-analysis of low-density lipoprotein receptor related protein in Alzheimer's disease (2005) (31)
Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease (2015) (30)
Microglial cells and amyloid ? protein (A?) deposition: association with A?40-containing plaques (1995) (30)
Sample Size Estimation for Alzheimer’s Disease Trials from Japanese ADNI Serial Magnetic Resonance Imaging (2016) (30)
Dual antitumor mechanisms of Notch signaling inhibitor in a T‐cell acute lymphoblastic leukemia xenograft model (2009) (29)
The inhibition of gamma-secretase as a therapeutic approach to Alzheimer's disease. (2004) (29)
Solid-phase synthesis of photoaffinity probes: highly efficient incorporation of biotin-tag and cross-linking groups. (2003) (29)
Roles of lysosomotropic agents on LRRK2 activation and Rab10 phosphorylation (2020) (28)
Enhanced Accumulation of Phosphorylated α-Synuclein and Elevated β-Amyloid 42/40 Ratio Caused by Expression of the Presenilin-1 ΔT440 Mutant Associated with Familial Lewy Body Disease and Variant Alzheimer's Disease (2007) (28)
The past, present, and future of disease-modifying therapies for Alzheimer’s disease (2017) (28)
Association study of the Ubiquilin gene with Alzheimer's disease (2006) (27)
Loss of kallikrein‐related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice (2018) (27)
Enhanced accumulation of phosphorylated alpha-synuclein and elevated beta-amyloid 42/40 ratio caused by expression of the presenilin-1 deltaT440 mutant associated with familial Lewy body disease and variant Alzheimer's disease. (2007) (27)
gamma-secretase as a therapeutic target for treatment of Alzheimer's disease. (2006) (27)
Pathological biochemistry of alpha-synucleinopathy. (2007) (26)
Atypical amyloid (Aβ) deposition in the cerebellum in Alzheimer’s disease: an immunohistochemical study using end-specific Aβ monoclonal antibodies (1996) (26)
Diffuse plaques in the cerebellum and corpus striatum in Down's syndrome contain amyloid beta protein (A beta) only in the form of A beta 42(43). (1996) (26)
Phantom criteria for qualification of brain FDG and amyloid PET across different cameras (2016) (26)
Analysis of Neurons Created from Wild-Type and Alzheimer's Mutation Knock-In Embryonic Stem Cells by a Highly Efficient Differentiation Protocol (2003) (26)
Contribution of the γ-Secretase Subunits to the Formation of Catalytic Pore of Presenilin 1 Protein* (2012) (26)
[alpha-Synuclein and familial Parkinson's disease]. (1999) (26)
α-T-catenin is expressed in human brain and interacts with the Wnt signaling pathway but is not responsible for linkage to chromosome 10 in Alzheimer’s disease (2007) (26)
Ku70 Alleviates Neurodegeneration in Drosophila Models of Huntington's Disease (2011) (26)
Parallel synthesis of DAPT derivatives and their γ-secretase-inhibitory activity (2004) (25)
Synthesis of biotinylated photoaffinity probes based on arylsulfonamide γ-secretase inhibitors (2006) (25)
Chronic cerebral hypoperfusion shifts the equilibrium of amyloid β oligomers to aggregation-prone species with higher molecular weight (2019) (25)
Alpha-T-catenin is expressed in human brain and interacts with the Wnt signaling pathway but is not responsible for linkage to chromosome 10 in Alzheimer's disease. (2004) (25)
A 3’-UTR polymorphism in the oxidized LDL receptor 1 gene increases Aβ40 load as cerebral amyloid angiopathy in Alzheimer’s disease (2005) (24)
Comparable amyloid β-protein (Aβ) 42(43) and Aβ40 deposition in the aged monkey brain (1996) (24)
Synthetic ceramide analogues increase amyloid-β 42 production by modulating γ-secretase activity. (2015) (23)
Paired helical filaments in astrocytes: electron microscopy and immunohistochemistry in a case of atypical Alzheimer's disease (2004) (23)
Mostly separate distributions of CLAC- versus Abeta40- or thioflavin S-reactivities in senile plaques reveal two distinct subpopulations of beta-amyloid deposits. (2004) (23)
Animal Model Age-Related Amyloid b Deposition in Transgenic Mice Overexpressing Both Alzheimer Mutant Presenilin 1 and Amyloid b Precursor Protein Swedish Mutant Is Not Associated with Global Neuronal Loss (2000) (23)
Lack of Correlation between the Kinase Activity of LRRK2 Harboring Kinase-Modifying Mutations and Its Phosphorylation at Ser910, 935, and Ser955 (2014) (23)
The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype (1995) (22)
Molecular cloning and characterization of CALP / KChIP 4 , a novel EF-hand protein interacting with presenilin 2 and voltage-gated potassium channel subunit Kv 4 (2002) (22)
THIS ARTICLE HAS BEEN RETRACTED: Pathological biochemistry of α‐synucleinopathy (2007) (21)
Partial loss of CALM function reduces Aβ42 production and amyloid deposition in vivo. (2016) (21)
Effect of helical conformation and side chain structure on γ-secretase inhibition by β-peptide foldamers: insight into substrate recognition. (2013) (21)
Conformational Changes in Transmembrane Domain 4 of Presenilin 1 Are Associated with Altered Amyloid-β 42 Production (2016) (21)
Pax6-5a promotes neuronal differentiation of murine embryonic stem cells. (2009) (20)
Behavioral and electrophysiological evidence for a neuroprotective role of aquaporin-4 in the 5xFAD transgenic mice model (2020) (20)
Clinical and biomarker investigation of a patient with a novel presenilin-1 mutation (A431V) in the mild cognitive impairment stage of Alzheimer’s Disease (2002) (20)
Single Chain Variable Fragment against Nicastrin Inhibits the γ-Secretase Activity* (2009) (20)
A polymorphism within intron 11 of the tau gene is not increased in frequency in patients with sporadic Alzheimer's disease, nor does it influence the extent of tau pathology in the brain (2002) (19)
Influence of Signal Intensity Non-Uniformity on Brain Volumetry Using an Atlas-Based Method (2012) (19)
Differential effects of familial parkinson mutations in LRRK2 revealed by a systematic analysis of autophosphorylation. (2013) (19)
Calcium-responsive transactivator (CREST) protein shares a set of structural and functional traits with other proteins associated with amyotrophic lateral sclerosis (2015) (19)
Amyloid beta protein in plasma as a diagnostic marker for Alzheimer's disease. (1998) (19)
Binding of longer Aβ to transmembrane domain 1 of presenilin 1 impacts on Aβ42 generation (2014) (19)
Phosphorylated alpha-synuclein in normal mouse brain. (2004) (19)
Ca2+/calmodulin-dependent protein kinase II immunoreactivity in Lewy bodies (2004) (19)
Immunoreactivity of phage library-derived human single-chain antibodies to amyloid beta conformers in vitro. (2007) (18)
Three dimensional structure of signal peptide peptidase (2009) (18)
Improved volumetric measurement of brain structure with a distortion correction procedure using an ADNI phantom. (2013) (18)
Effects of image distortion correction on voxel-based morphometry. (2012) (18)
Convenient synthesis of photoaffinity probes and evaluation of their labeling abilities. (2007) (18)
Amyloid beta protein (A beta) deposition in dementia with Lewy bodies: predominance of A beta 42(43) and paucity of A beta 40 compared with sporadic Alzheimer's disease. (1998) (18)
Primary cultures of neuronal and non-neuronal rat brain cells secrete similar proportions of amyloid beta peptides ending at A beta40 and A beta42. (1999) (18)
Effects of sex, educational background, and chronic kidney disease grading on longitudinal cognitive and functional decline in patients in the Japanese Alzheimer's Disease Neuroimaging Initiative study (2018) (18)
Molecular interactions between presenilin and calpain: inhibition of m-calpain protease activity by presenilin-1, 2 and cleavage of presenilin-1 by m-, mu-calpain. (2000) (17)
The presenilin 1 mutation (M146V) linked to familial Alzheimer's disease attenuates the neuronal differentiation of NTera 2 cells. (1998) (17)
Clinical and cognitive characteristics of preclinical Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative cohort (2018) (17)
Focal appearance of cerebellar torpedoes associated with discrete lesions in the cerebellar white matter (2004) (17)
State‐of‐the‐art of lumbar puncture and its place in the journey of patients with Alzheimer's disease (2021) (16)
Molecular Identification of AMY, an Alzheimer Disease Amyloid‐Associated Protein (2003) (16)
A novel non-canonical Notch signaling regulates expression of synaptic vesicle proteins in excitatory neurons (2016) (15)
Lewy Bodies: Purification from Diffuse Lewy Body Disease Brains a (1996) (15)
Long non-coding RNA NEAT1_1 ameliorates TDP-43 toxicity in in vivo models of TDP-43 proteinopathy (2021) (15)
Self-assembly of FUS through its low-complexity domain contributes to neurodegeneration (2018) (15)
A clinical and neuropathological study of an unusual case of sporadic tauopathy. A variant of corticobasal degeneration? (2002) (15)
Association study of Notch 4 polymorphisms with Alzheimer’s disease (2004) (15)
An intronic polymorphism in the presenilin-1 gene does not influence the amount or molecular form of the amyloid β protein deposited in Alzheimer's disease (1997) (15)
Equal sensitivity of early and late scans after injection of FDG for the detection of Alzheimer pattern: an analysis of 3D PET data from J-ADNI, a multi-center study (2013) (15)
Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. (2006) (14)
Lower Serum Calcium as a Potentially Associated Factor for Conversion of Mild Cognitive Impairment to Early Alzheimer's Disease in the Japanese Alzheimer's Disease Neuroimaging Initiative. (2019) (14)
Collagen XXV promotes myoblast fusion during myogenic differentiation and muscle formation (2019) (14)
Tau accumulation in a patient with pallidonigroluysian atrophy (2001) (14)
Familial Amyotrophic Lateral Sclerosis-linked Mutations in Profilin 1 Exacerbate TDP-43-induced Degeneration in the Retina of Drosophila melanogaster through an Increase in the Cytoplasmic Localization of TDP-43* (2016) (14)
Role of apolipoprotein E in β-amyloidogenesis: Isoform-specific effects on protofibril to fibril conversion of Aβ in vitro and brain Aβ deposition in vivo. (2018) (14)
Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease (2020) (14)
Aβ42, Presenilins, and Alzheimer’s Disease (1998) (14)
Efficient four‐drug cocktail therapy targeting amyloid‐β peptide for Alzheimer's disease (2010) (14)
Bunina bodies in neurons of the medullary reticular formation in amyotrophic lateral sclerosis (2004) (13)
Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force (2019) (13)
326 The βAPP717 Alzheimer mutation increases the percentage of plasma amyloid β protein ending at Aβ42(43) (1996) (12)
Linking the Mini-Mental State Examination, the Alzheimer’s Disease Assessment Scale–Cognitive Subscale and the Severe Impairment Battery: evidence from individual participant data from five randomised clinical trials of donepezil (2020) (12)
Disease‐modifying therapy for Alzheimer's disease: Challenges and hopes (2013) (12)
Microglial cells and amyloid β protein (Aβ) deposition: association with Aβ40-plaques (1995) (12)
Inhibition of γ-secretase activity by a monoclonal antibody against the extracellular hydrophilic loop of presenilin 1. (2013) (12)
Atypical amyloid (A beta) deposition in the cerebellum in Alzheimer's disease: an immunohistochemical study using end-specific A beta monoclonal antibodies. (1996) (11)
Development of photoaffinity probes for gamma-secretase equipped with a nitrobenzenesulfonamide-type cleavable linker. (2009) (11)
Primary progressive aphasia with focal glial tauopathy (2000) (11)
Molecular Dissection of Domains in Mutant Presenilin 2 That Mediate Overproduction of Amyloidogenic Forms of Amyloid β Peptides (1998) (11)
Assembly and activation of the γ-secretase complex: roles of presenilin cofactors (2004) (11)
Visualizing modules of coordinated structural brain atrophy during the course of conversion to Alzheimer's disease by applying methodology from gene co-expression analysis (2019) (10)
Roles of Collagen XXV and Its Putative Receptors PTPσ/δ in Intramuscular Motor Innervation and Congenital Cranial Dysinnervation Disorder. (2019) (10)
The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI‐3 updates and global perspectives (2021) (10)
ALS-linked cytoplasmic FUS assemblies are compositionally different from physiological stress granules and sequester hnRNPA3, a novel modifier of FUS toxicity (2021) (10)
Immunocytochemical study of D-aspartate in the 2068 rat pheochromocytoma cell line (2001) (10)
Concise and Short Synthesis of Functionalized 5,6-Dihydropyridin-2-ones by Means of Palladium(0)-Catalyzed Cross-Coupling of Ketene Aminal Phosphates (2006) (10)
Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study (2019) (10)
Semagacestat for treatment of Alzheimer's disease. (2013) (9)
Seeding Activity-Based Detection Uncovers the Different Release Mechanisms of Seed-Competent Tau Versus Inert Tau via Lysosomal Exocytosis (2019) (9)
Parallel synthesis of DAPT derivatives and their gamma-secretase-inhibitory activity. (2004) (8)
Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial‐Ready Cohort study (2021) (8)
βAPP γ‐secretase and SREBP site 2 protease are two different enzymes (1998) (8)
Alterations in a Transgenic Mouse Model Expressing Human-Synuclein under Oligodendrocyte Promoter : Implications for Multiple System Atrophy (2005) (8)
Characterization of the unique In Vitro effects of unsaturated fatty acids on the formation of amyloid β fibrils (2019) (8)
Molecular pathogenesis of Alzheimer's disease. (2003) (8)
Comparable amyloid beta-protein (A beta) 42(43) and A beta 40 deposition in the aged monkey brain. (1996) (8)
Improved volumetric measurement of brain structure with a distortion correction procedure using an ADNI phantom. (2013) (8)
Actin-binding protein filamin-A drives tau aggregation and contributes to progressive supranuclear palsy pathology (2022) (8)
[Mono-radiculopathy multiplex--multiple infarction of the cauda equina caused by intravascular lymphomatosis]. (1991) (8)
Targeting MicroRNA-485-3p Blocks Alzheimer’s Disease Progression (2021) (7)
Collagenous Alzheimer amyloid plaque component impacts on the compaction of amyloid-β plaques (2020) (7)
Assembly and activation of the gamma-secretase complex: roles of presenilin cofactors. (2004) (7)
Abeta42, presenilins, and Alzheimer's disease. (1998) (7)
Imago Mundi, Imago AD, Imago ADNI (2014) (7)
Calcium-responsive transactivator (CREST) toxicity is rescued by loss of PBP1/ATXN2 function in a novel yeast proteinopathy model and in transgenic flies (2018) (6)
Experimental detection of proteolytic activity in a signal peptide peptidase of Arabidopsis thaliana (2013) (6)
Disseminated Pneumocystis Carinii Infection in a Hemophiliac Patient with Acquired Immunodeficiency Syndrome (1992) (6)
Notable Drug–Drug Interaction Between Etizolam and Itraconazole in Poor Metabolizers of Cytochrome P450 2C19 (2017) (6)
The nigro-striatal and nigro-amygdaloid pathways undergo different degeneration processes in brains of dementia with Lewy bodies (2005) (6)
Differential involvement of insulin receptor substrate (IRS)-1 and IRS-2 in brain insulin signaling is associated with the effects on amyloid pathology in a mouse model of Alzheimer's disease (2021) (6)
Microglial cells and amyloid beta protein (A beta) deposition; association with A beta 40-containing plaques. (1995) (6)
Synthesis and biological activity of N-substituted spiro[benzoxazepine-piperidine] Aβ-peptide production inhibitors (2008) (6)
Using Digital Tools to Advance Alzheimer’s Drug Trials During a Pandemic: The EU/US CTAD Task Force (2021) (6)
New photocleavable linker: α-thioacetophenone-type linker. (2014) (6)
Inter-laboratory variation when using a unified test procedure for INNO-BIA AlzBio3 (2013) (5)
A Novel Method to Estimate Long‐Term Chronological Changes From Fragmented Observations in Disease Progression (2018) (5)
[Pathogenesis of Alzheimer's disease: implications from amyloid research front]. (2004) (5)
Alzheimer disease research in Japan: public funding (2006) (5)
Novel Notch-sparing gamma-secretase inhibitors derived from a peroxisome proliferator-activated receptor agonist library. (2010) (5)
Some unusual responses of astrocytes to ghost tangles in a long duration case of juvenile Alzheimer's disease: an electron microscopic study (1996) (5)
Presenilin-1 C410Y Alzheimer Disease Plaques Contain Synaptic Proteins (2007) (5)
Linking the Clinical Dementia Rating Scale-Sum of Boxes, the Clinician's Interview-Based Impression Plus Caregiver Input, and the Clinical Global Impression Scale: Evidence based on Individual Participant Data from Five Randomized Clinical Trials of Donepezil. (2021) (4)
Dissection of the polygenic architecture of neuronal Aβ production using a large sample of individual iPSC lines derived from Alzheimer’s disease patients (2022) (4)
Corrigendum to “Three-dimensional structure of the γ-secretase complex” [Biochem. Biophys. Res. Commun. 343 (2006) 525–534] (2006) (4)
Influence of Parameter Settings in Voxel-based Morphometry 8 (2014) (4)
Mechanisms of Neuron Death in Neurodegenerative Diseases of the Elderly (1998) (4)
Highly Efficient Synthesis of Medium-Sized Lactams via Intramolecular Staudinger—aza-Wittig Reaction of ω-Azido Pentafluorophenyl Ester: Synthesis and Biological Evaluation of LY411575 Analogues. (2004) (4)
Tauroursodeoxycholic Acid Attenuates Diet-Induced and Age-Related Peripheral Endoplasmic Reticulum Stress and Cerebral Amyloid Pathology in a Mouse Model of Alzheimer’s Disease (2021) (4)
[Pathogenesis of Parkinson's disease: implications from familial Parkinson's disease]. (2005) (4)
Longitudinal gray-matter volume change in the default-mode network: utility of volume standardized with global gray-matter volume for Alzheimer’s disease: a preliminary study (2014) (4)
Lipid flippase dysfunction as a therapeutic target for endosomal anomalies in Alzheimer’s disease (2022) (4)
[Beta- and gamma-secretases]. (2006) (4)
[Chronic human colchicine myopathy]. (1990) (4)
Therapeutic Targets for Alzheimer’s Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report (2022) (4)
Evaluation of PiB visual interpretation with CSF Aβ and longitudinal SUVR in J-ADNI study (2019) (4)
High Tissue Content of Soluble (31-40 is Linked to Cerebral Amyloid Angiopathy (2007) (4)
Stage vs. Subtype Hypothesis in Alzheimer's Disease: A Multi-Cohort and Longitudinal Bayesian Clustering Study (2021) (3)
Ku 70 Alleviates Neurodegeneration in Drosophila Models of Huntington ’ s Disease (2011) (3)
[Alzheimer's disease: basic aspects]. (2000) (3)
Lemur tail kinase 1 (LMTK1) regulates the endosomal localization of β-secretase BACE1. (2021) (3)
Age, APOE e4, and ethnic effect on [C-11]PiB in multinational ADNI studies: direct comparison of J-ADNI, US-ADNI and AIBL data (2011) (3)
Automated Evaluation of Conventional Clock-Drawing Test Using Deep Neural Network: Potential as a Mass Screening Tool to Detect Individuals With Cognitive Decline (2022) (3)
[Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and alpha-synuclein]. (1999) (3)
Short Communication Full-Length Amyloid-f3(1-42(43)) and Amino-Terminally Modified and Truncated Amyloid-(42(43) Deposit in Diffuse Plaques (2007) (3)
Chronic neuropsychiatric sequelae of SARS‐CoV‐2: Protocol and methods from the Alzheimer's Association Global Consortium (2022) (3)
Synthesis of biotinylated photoaffinity probes based on arylsulfonamide gamma-secretase inhibitors. (2006) (3)
Analytical method for beta-amyloid fibrils using CE-laser induced fluorescence and its application to screening for inhibitors of beta-amyloid protein aggregation. (2007) (3)
Different AT(N) profiles and clinical progression classified by two different N markers using total tau and neurofilament light chain in cerebrospinal fluid (2022) (3)
Tauopathy: An overview (2006) (3)
Amyloid β Peptides and Presenilins in the Pathogenesis of Alzheimer's Disease (1999) (3)
The impact of COVID-19 pandemic on the utilization of ambulatory care for patients with chronic neurological diseases in Japan: Evaluation of an administrative claims database. (2021) (3)
Efficacy and Cost-effectiveness of Promotion Methods to Recruit Participants to an Online Screening Registry for Alzheimer Disease Prevention Trials: Observational Study (2020) (2)
Single chain variable fragment against nicastrin inhibits the γ-secretase activity (2009) (2)
Evaluation of major national dementia policies and health‐care system preparedness for early medical action and implementation (2022) (2)
[beta-amyloid cascade: current status and future directions]. (2000) (2)
CHRONIC CEREBRAL HYPOPERFUSION INCREASES AMYLOID PLAQUES BY ACCELERATING AMYLOID BETA AGGREGATION IN APP/PS1 TRANSGENIC MICE (2018) (2)
[Molecular targeted therapy in Alzheimer disease]. (2010) (2)
[Molecular cell biology of presenilins]. (1999) (2)
[Chronic inflammatory demyelinating polyradiculoneuropathy of acute onset: relapse after temporary improvement by plasma exchange and longstanding remission by corticosteroid therapy]. (1989) (2)
Correction: Ku70 Alleviates Neurodegeneration in Drosophila Models of Huntington's Disease (2012) (2)
Multi-cohort and longitudinal Bayesian clustering study of stage and subtype in Alzheimer’s disease (2022) (2)
Focusing on β-amyloid: Report of the 35th Annual Meeting of the Society for Neuroscience (2006) (2)
In Vivo Effects of Notch Signaling Inhibitor on Tumor Growth and Its Mechanism of Action. (2006) (2)
Peripheral Blood BRCA1 Methylation Positively Correlates with Major Alzheimer’s Disease Risk Factors (2021) (2)
Purification of Lewy Bodies and Identification of α-Synuclein as a Major Component of Lewy Bodies (2000) (2)
Corrigendum to “Common anti-apoptotic roles of parkin and α-synuclein in human dopaminergic cells” [Biochem. Biophys. Res. Commun. 332 (2005) 233–240] (2005) (1)
[Alzheimer's disease: focus on beta-amyloid and gamma-secretase]. (2004) (1)
Differential effects of diet- and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimer’s disease (2019) (1)
BIN1 REGULATES BACE1 TRAFFICKING AND AB PRODUCTION (2014) (1)
Imago Mundi, Imago AD, Imago ADNI (2014) (1)
Cognitive impairment networks in Alzheimer's disease: Analysis of three double-blind randomized, placebo-controlled, clinical trials of donepezil (2022) (1)
Early- and subsequent- response of cognitive functioning in Alzheimer's disease: Individual-participant data from five pivotal randomized clinical trials of donepezil. (2022) (1)
795 Post-secretory catabolism of ß-amyloid in brain (1996) (1)
The Biology of the Presenilin Complexes (2007) (1)
[Genetic factors in the pathogenesis of Alzheimer's disease: roles of beta-amyloid and presenilins]. (1998) (1)
P3-401 Ubiquitination of alpha-synuclein (2004) (1)
Experts' perception of support for people with dementia and their families during the COVID‐19 pandemic (2021) (1)
Time to onset of drug-induced parkinsonism: Analysis using a large Japanese adverse event self-reporting database. (2022) (1)
The first results of amyloid imaging in Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) study (2010) (1)
Structural domain requirements for presenilin endoproteolysis and Aβ42 overproduction (2000) (1)
Attempt to Predict A/T/N-Based Alzheimer’s Disease Cerebrospinal Fluid Biomarkers Using a Peripheral Blood DNA Methylation Clock (2020) (1)
P4-083 Is there a relation between APOE expression and amyloid depositions in the brain of Alzheimer's disease cases? (2004) (1)
Molecular Pathogenesis and Disease-modifying Therapies of Alzheimer’s Disease and Related Disorders (2022) (1)
Binding of longer Aβ to transmembrane domain 1 of presenilin 1 impacts on Aβ42 generation (2014) (1)
PL-4-2 Formation and function of the gamma-secretase complex (2004) (1)
α-Synuclein and dementia with Lewy bodies (2000) (1)
Initial exploration of a brain age score based on validated computerized cognitive assessments in Japanese individuals (2020) (1)
Synthesis and biological activity of N-substituted spiro[benzoxazepine-piperidine] Abeta-peptide production inhibitors. (2008) (1)
[Molecular pathology and therapeutic perspectives of Alzheimer's disease]. (2005) (1)
Extracellular α-synuclein levels are regulated by neuronal activity (2018) (1)
[The mechanism of A beta production and its inhibition as a therapeutic strategy for the prevention of Alzheimer's disease]. (2002) (1)
Regional distribution of D-amino acids in the rat brain (1997) (1)
Quantifying the heterogeneity of cognitive functioning in Alzheimer’s disease to extend the placebo-treatment dichotomy: Latent class analysis of individual-participant data from five pivotal randomized clinical trials of donepezil (2021) (1)
The use of lumbar puncture and safety recommendations in Alzheimer's disease: a plain language summary. (2022) (1)
[Toward Preclinical Trials for Alzheimer's Disease]. (2017) (1)
P4-376 TAK-070, a non-peptidic bace inhibitor inhibits secretion of amyloid beta 40/42 and enhances sappalpha production in neuronal cell cultures (2004) (1)
Alzheimer’s Disease Research in Japan: A Short History, Current Status and Future Perspectives toward Prevention (2021) (1)
Author Correction: Collagen XXV promotes myoblast fusion during myogenic differentiation and muscle formation (2019) (1)
P1-235 CLAC-positive senile plaques in Alzheimer brains: mutually exclusive distribution to Aβ40 and acquisition of protease resistance (2004) (1)
Collagenous Alzheimer amyloid plaque component impacts on the compaction of amyloid-β plaques (2020) (1)
[Beta-amyloid protein: recent progress in basic research and therapeutic approaches]. (2001) (1)
Efficacy and Cost-effectiveness of Promotion Methods to Recruit Participants to an Online Screening Registry for Alzheimer Disease Prevention Trials: Observational Study (Preprint) (2020) (1)
Correction of scanner differences in multicenter J-ADNI and U.S.-ADNI PET studies (2013) (0)
O1-02-07 Different actions of dipeptidic compounds on presenilins define the enzyme specificity of γ-secretase inhibitor (2006) (0)
[Japanese clinical statistical data of progressive supranuclear palsy]. (1992) (0)
Calcium-responsive transactivator (CREST) protein shares a set of structural and functional traits with other proteins associated with amyotrophic lateral sclerosis (2015) (0)
The amyloid-β pathway in Alzheimer's disease: a plain language summary. (2023) (0)
P4-069 Modeling amyloid β-peptide transport across the blood-brain barrier in TR-BBB cells (2006) (0)
Compositional analysis of ALS-linked stress granule-like structures reveals factors and cellular pathways dysregulated by mutant FUS under stress (2021) (0)
Tau-related dysfunction of BRCA1 lead to reduced neuronal plasticity in Alzheimer’s disease (P2.191) (2018) (0)
Alzheimer disease: From basic study to disease-modifying therapy (2009) (0)
Intrabody against immature nicastrin disrupts the proper folding and the glycosyl maturation of the extracellular domain of nicastrin (2009) (0)
J-ADNI and selection of cognition measures (2010) (0)
The role of Rab7L1 phosphorylation by LRRK2, a causative gene product for Parkinsonʹs disease (2017) (0)
703 Detection of isoaspartyl form of amyloid β protein in Aizheimer's disease brains (1996) (0)
2. Molecular pathogenesis of Alzheimer's disease : Dementia of old people: Recent advances in epidemiology, diagnosis, treatment, care, and research (2003) (0)
Alzheimer's Disease: Towards Very Early Diagnosis and Treatment: ―超早期の診断と治療をめざして (2016) (0)
Aβ as a homeostatic negative regulator of synaptic function? (2000) (0)
[Bilateral horizontal gaze palsy due to hemi-tegmental lesion in a case of pontine infarction]. (1988) (0)
CLINICAL AND COGNITIVE CHARACTERISTICS OF PARTICIPANTS WITH PRECLINICAL ALZHEIMER’S DISEASE IN THE JAPANESE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (2019) (0)
P1-059 Overexpression of human alpha-synuclein in transgenic C. elegans: Effects of pathogenic mutations and phosphorylation (2006) (0)
Amyloid f Protein Deposition in Normal Aging Has the Same Characteristics as That in Alzheimer's Disease Predominance of Af42(43) and Association of A340 with Cored Plaques (2007) (0)
Future Perspectives of Alzheimer Disease Research (2011) (0)
Immunocytochemical studies on β-amyloidogenesis (1994) (0)
Strengthening/Building Alzheimer’s Disease Global Clinical Trial Site Capabilities and Capacity in and for Emerging Markets. Lessons Learned from Japan (2014) (0)
α-SYNUCLEIN IS A COMPONENT OF LEWY BODIES (1998) (0)
P3-416 Probing the structural changes of presenilin 1 by substituted-cysteine accessibility method (2006) (0)
EPIGENETIC REGULATION OF BRCA1 IN ALZHEIMER’S DISEASE: EVALUATION OF POSTMORTEM BRAIN AND MODEL MICE REVEALS IMPORTANCE OF AGGREGATED TAU (2016) (0)
S4-01-02: Structure of the catalytic pore of gamma-secretase (2008) (0)
Purification andCharacterization ofLewyBodies fromtheBrains ofPatients withDiffuse Lewy BodyDisease (1996) (0)
[Analysis of alpha-synuclein and its significance]. (2004) (0)
ENVISION: A phase 3b/4 randomized, double‐blind, placebo‐controlled, parallel‐group study to verify the clinical benefit of aducanumab in participants with early Alzheimer’s disease (2022) (0)
Two distinct pathways leading to retinal degeneration in transgenic Drosophila melanogaster overexpressing human FUS (2013) (0)
Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease (2015) (0)
ALZHEIMER’S DISEASE Advances in Genetics, Molecular and Cellular Biology ALZHEIMER’S DISEASE Advances in Genetics, Molecular and Cellular Biology (2013) (0)
Challenges to the enigma of γ-secretase and to Alzheimer’s disease (2006) (0)
Functional analysis of γ-secretase, which concerns with generation of amyloid β-peptides (Aβ) (2006) (0)
399 The familial Alzheimer disease-linked mutations of Val717 of amyloid precursor protein is specific for the increased secretion of the longer Aβ (1996) (0)
Introduction of "Genji Chigusako" possessed by Chikuyu-Bunko (2) : 1 Kiritsuboko〜6 Suetsumuhanako (2014) (0)
[DIAN/DIAN-J/DIAN-TU]. (2017) (0)
Molecular interactions between presenilin and calpain: inhibition of m-calpain protease activity by presenilin and cleavage of presenilin-1 by calpain (2000) (0)
Introduction of "Genji Chigusako" possessed by Chikuyu-bunko (3) :7 Momijinogako〜12 Sumako (2014) (0)
Collagen XXV promotes myoblast fusion during myogenic differentiation and muscle formation (2019) (0)
P4-162: LRRK2 in Lewy bodies of Parkinson’s disease and dementia with Lewy bodies (2006) (0)
FDG-PET Study of Patient with a Novel Presenilin4 Mutation in the Mild Cognitive Impairment Stage of Aizheimer's Disease (2001) (0)
O3-05-04 Roles of presenilin cofactors in the assembly and activity of {gamma}-secretase complex (2004) (0)
Worldwide ADNI Update – July , 2012 (2013) (0)
Personalized Prediction of Alzheimer's Disease and Its Treatment Effects by Donepezil: An Individual Participant Data Meta-Analysis of Eight Randomized Controlled Trials. (2022) (0)
P-545 DIVERGENT SYNTHESIS OF MOLECULAR PROBES BASED ON CAPROLACTAM γ-SECRETASE INHIBITORS AND THEIR MOLECULAR TARGETS (2006) (0)
Frequency of preclinical Alzheimer's disease in Japanese clinical study settings: a meta-analysis (2022) (0)
Influence of APOE genotype on global and regional amyloid deposition: Results from three WW-ADNI [C-11]PiB data (2012) (0)
Quality of Life – 5 Dimensions ( EQ-5 D ) scale ( proxy version ) , 15 the Quality of Life in Alz (2014) (0)
Effects of APOE-ε4 on regional cerebral amyloid deposition and gray matter atrophy in mild cognitive impairment with PiB-PET-confirmed amyloid pathology: Results from J-ADNI (2013) (0)
Lipid flippase dysfunction as a novel therapeutic target for endosomal anomalies in Alzheimer’s disease (2021) (0)
Image interpretation method of [C-11]BF-227 amyloid PET in J-ADNI (2013) (0)
[J-ADNI and very early treatment of Alzheimer's disease]. (2012) (0)
[Recommendations (Proposal) for promoting research for overcoming neurological diseases 2020]. (2022) (0)
The clinical application of optimized AT(N) classification in Alzheimer’s clinical syndrome (ACS) and non-ACS conditions (2023) (0)
Neuroscience Committee (2008) (0)
AMYLOID PLAQUES IN GUAM AMYOTROPHIC LATERAL SCLEROSIS/AND PARKINSONISM-DEMENTIA COMPLEX (ALS/PDC) CONTAIN SPECIES OF Aβ SIMILAR TO THOSE FOUND IN THE AMYLOID PLAQUES OF ALZHEIMERʼS DISEASE (AD) AND PATHOLOGICAL AGING (PA) (1998) (0)
P1-114 Pathological effects of CLAC in the brains of APP/CLAC-P double transgenic mice (2006) (0)
P1-478: Isoform-specific effects of apolipoprotein E on the stability of Abeta protofibrils (2008) (0)
[Alzheimer disease: experimental approaches to genetic and environmental risk factors]. (2013) (0)
TAU-RELATED DYSFUNCTION OF BRCA1 LEADS TO REDUCED NEURONAL PLASTICITY IN ALZHEIMER’S DISEASE (2018) (0)
Machine-learning classification of MR scans in Alzheimer's disease based on tensor-based morphometry (2013) (0)
The impact of COVID-19 pandemic on the provision of ambulatory care for patients with chronic neurological diseases in Japan: evaluation of an administrative claims database (2021) (0)
A neuroprotective role of aquaporin-4 against other than amyloid β deposition or neuroinflammation in the 5xFAD transgenic mice model. (2020) (0)
CAN A BLOOD-BASED Aβ42 SURROGATE MARKER BE PRACTICALLY USED FOR SCREENING OF BRAIN Aβ42 ACCUMULATION? (2017) (0)
VI. Lifestyle Diseases and Dementia: Update on Pathophysiology, Prevention, and Treatment (2019) (0)
Effect of apolipoprotein E-ε4 status on brain atrophy in 1-year repeat MRI data from cognitively normal elderly individuals (2013) (0)
DEVELOPMENT OF A GUIDELINE ON THE CLINICAL EVALUATION OF DRUGS FOR ALZHEIMER'S DISEASE IN JAPAN (INTERIM REPORT) (2014) (0)
Discussions on laminin as possible biomarkers for neurodegenerative dementia (2004) (0)
BetaAPP gamma-secretase and SREBP site 2 protease are two different enzymes. (1998) (0)
[Recent advances in Alzheimer's disease-related gamma-secretase complex]. (2004) (0)
Behavioral and electrophysiological evidence for a neuroprotective role of aquaporin-4 in the 5xFAD transgenic mice model (2020) (0)
Change in long‐term care service usage in Japan following the COVID‐19 pandemic: A survey using a nationwide statistical summary in 2018–2021 (2022) (0)
[Molecular mechanism of Alzheimer disease]. (2002) (0)
Amyloid and presenilins in the pathobiology of Alzheimer’s disease (2001) (0)
Biochemical Analysis of Tau and α-Synuclein in Neurodegenerative Diseases (2002) (0)
[On the mechanism of symptomatic development in syringomyelobulbia]. (1988) (0)
P3-185 Relationships in Alzheimer’s disease between the extent of Aβ deposition in cerebral blood vessel walls, as cerebral amyloid angiopathy, and the amount of cerebrovascular smooth muscle cells and collagen (2006) (0)
Discussions on phosphorylated tau and other biochemical markers (2004) (0)
PRESENILIN AND AMYLOIDOGENESIS: A STRUCTURE-FUNCTION RELATIONSHIP STUDY ON PRESENILIN 2 (2002) (0)
Alzheimer's disease: From molecular pathology to disease-modifying therapy (2011) (0)
Corrigendum to “Development of photoaffinity probes for γ-secretase equipped with a nitrobenzenesulfonamide-type cleavable linker” [Bioorg. Med. Chem. Lett. 19 (2009) 6869] (2010) (0)
P4-322 Presenilin-1 is a molecular target of a dipeptidic γ-secretase inhibitor, DAPT (2004) (0)
Functional Analysis of the Presenilin Complex and γ-Secretase Activity (2004) (0)
The integrity of carboxyl terminus of presenilin 2 is essential for its functions (2000) (0)
Effects of APOE-ε4 on regional cerebral amyloid deposition and glucose metabolism in amnestic mild cognitive impairment with amyloid pathology confirmed by PiB-PET: Results from J-ADNI (2012) (0)
O4-03-03: C-terminal PAL motif of presenilin 1 comprises the subsite of gamma-secretase within the catalytic pore (2008) (0)
Chronic cerebral hypoperfusion shifts the equilibrium of amyloid β oligomers to aggregation-prone species with higher molecular weight (2019) (0)
Pathophysiological role of proteolytic cleavage of neuroligins (2013) (0)
Characteristics of the baseline plasma homocysteine levels and the correlation with risk factors and cognition in Japanese-ADNI (J-ADNI) biomarker study (2010) (0)
Introduction of "Genji Chigusako" possessed by Chikuyu-Bunko (5) : 19 Usugumoko〜24 Kochoko ( Deeply analyze the process of Japan's fast expanded economy after World War 2) (2014) (0)
Outcome measures for Alzheimer's disease: A global inter-societal Delphi consensus. (2023) (0)
The Role of Parkinsonʼs Disease-associated Gene LRRK2 in the lysosomal homeostasis (2017) (0)
P4-207: Chemical biological analysis of gamma-secretase using arylsulfonamide-type inhibitors (2008) (0)
Cellular models of seeded aggregation of alpha-synuclein and tau (2011) (0)
Notes on "Sangyoku-chojisho" (2014) (0)
CONFORMATIONAL CHANGES IN THE TRANSMEMBRANE DOMAINS 4 AND 5 OF PRESENILIN 1 ASSOCIATED WITH ALTERED ABETA42 PRODUCTION (2014) (0)
171 Generation and deposition of amyloid β protein: Analyses using end- and modification-specific Aβ antibodies (1996) (0)
Pathophysiological impact of astrocyte-derived kallikrein-related peptidase 7 on Aβ metabolism in brain (2015) (0)
One-year reduction of glucose metabolism in the olfactory tract in Alzheimer's disease (2013) (0)
EFFECT OF APOLIPOPROTEIN E ε4 ALLELE ON PROGRESSION RATE OF COGNITIVE DECLINE IN PRODROMAL AND MILD ALZHEIMER’S DISEASE (2019) (0)
LOWER SERUM CALCIUM AS A POTENTIALLY ASSOCIATED FACTOR FOR CONVERSION OF MILD COGNITIVE IMPAIRMENT TO EARLY ALZHEIMER’S DISEASE IN JAPANESE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVES (2019) (0)
Contents Vol.19, 2019 (2020) (0)
Photoaffinity Probes for Alzheimer’s Disease (2007) (0)
Comparison of performance of early diagnostics of Alzheimer's disease between volume and thickness measurements of medial temporal structures using structural MRI (2012) (0)
Influence of APOE-ɛ4 genotype on global and regional Aβ deposition: Results from three WW-ADNI [C-11]PiB data studies (2012) (0)
[Current status and perspectives on the development of AD therapeutics based on amyloid cascade hypothesis]. (2013) (0)
, 5 intraneuronal neurofibrillary tangles , depressed brain (2003) (0)
Alpha-synuclein: identification in Lewy pathology and its pathogenic significance (2020) (0)
[Recommendations (Proposal) for promoting research for overcoming neurological diseases 2020]. (2021) (0)
[Dementia: progress in diagnosis and treatment; editorial, towards the preclinical treatment of Alzheimer disease]. (2011) (0)
Lessons from presenilin domain analysis: endoproteolytic processing and enhanced Aβ42 production mediated by FAD-linked variants (2001) (0)
Discussions on role of neprilysin and degradating system (2004) (0)
Novel phosphorylation of Rab29 that regulates its localization and lysosomal stress response in concert with LRRK2 (2022) (0)
PICALM regulates Aβ42 production by modulation of gamma-secretase trafficking (2012) (0)
[Molecular pathology and disease-modifying therapy of Alzheimer disease]. (2011) (0)
Very early treatment of Alzheimer's disease: experiences in J-ADNI and A4 study (2018) (0)
507 Distribution of Phosphorylated Tau in Neonatal and Adult Rat Brains (1996) (0)
Targeting microRNA‐485‐3p blocks Alzheimer's disease progression (2021) (0)
Correction: Koh et al. Targeting MicroRNA-485-3p Blocks Alzheimer’s Disease Progression. Int. J. Mol. Sci. 2021, 22, 13136 (2022) (0)
INCIDENCE AND FACTORS ASSOCIATED WITH THE ONSET OF POST-DURAL PUNCTURE HEADACHE: EXPERIENCE FROM THE JAPANESE ADNI AND REVIEW OF LITERATURE (2017) (0)
Differences in regional cerebral glucose metabolism between PiB-positive and -negative amnestic mild cognitive impairment: Results from J-ADNI (2012) (0)
Impact of the APOE promoter polymorphisms on aβ loading in AD brains (2000) (0)
An attempt to dissect the chemical communication system preparing the mating of Drosophila melanogaster (1981) (0)
Effect of a phantom-based distortion correction of MRI for assessment of Alzheimer's disease using a tensor-based morphmetry approach (2013) (0)
Performances of the plasma Aβ biomarker in longitudinal data (2020) (0)
Towards the Preclinical Treatment of Alzheimer Disease. (2011) (0)
Frequency of preclinical Alzheimer’s disease in Japanese clinical study settings: A meta‐analysis (2021) (0)
P3-262 Biochemical characterization of the core structure of tau filament (2004) (0)
Molecular cloning and characterization of a novel clic-related protein, parchorin, expressed in water-secreting cells (2000) (0)
Accumulation of Insoluble α-Synuclein in Human Lewy Body Diseases is Recapitulated in Transgenic Mice (2002) (0)
Concise and Short Synthesis of Functionalized 5,6‐Dihydropyridin‐2‐ones (X) by Means of Palladium(0)‐Catalyzed Cross‐Coupling of Ketene Aminal Phosphates (V). (2007) (0)
FTY720/Fingolimod, a sphingosine analogue, reduces beta-amyloid production in neurons (2013) (0)
Molecular pathology to disease modification of Alzheimer's disease (2019) (0)
P4-211: The functional roles of transmembrane domains of presenilin 1 in the formation of active gamma-secretase complex (2008) (0)
Casein kinase 1δ/ε phosphorylates fused in sarcoma (FUS) and ameliorates FUS-mediated neurodegeneration (2022) (0)
The role of Notch signaling in synaptogenesis (2007) (0)
[Recommendations (Proposal) for promoting research for overcoming neurological diseases 2020]. (2022) (0)
P4-208: Transmembrane domain 1 of presenilin 1 contributes to the formation of the catalytic pore of gamma-secretase (2008) (0)
Structure-function analysis of presenilins (2000) (0)
S2-03-04 Structure and function of gamma-secretase (2006) (0)
Two aspects of Suetsumuhana (2010) (0)
P3-412 Generation of monoclonal antibodies against the extracellular domain of nicastrin (2006) (0)
[Co-existence of clinical and immunohistochemical features of polymyositis and myasthenia gravis]. (1988) (0)
Parkinson ’ s Disease α-Catenin and Wnt Signaling Ox-Phose Genes and Alzheimer ’ s Disease NO and Tardive Dyskinesia Homocysteine and Oxyradical-Induced Cognitive Impairment (2004) (0)
NEURON-SPECIFIC METHYLOME ANALYSIS REVEALS NEW PATHOMECHANISM IN ALZHEIMER’S DISEASE BRAINS (2016) (0)
P3-348: Neuron-specific regulation of beta-secretase activity by sphingosine kinase (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Takeshi Iwatsubo?

Takeshi Iwatsubo is affiliated with the following schools:

University of Tokyo